Analyst Price Targets — NAMS
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| June 30, 2026 11:04 am | — | RBC Capital | $51.00 | $33.87 | TheFly | NewAmsterdam Pharma price target raised to $51 from $47 at RBC Capital |
| February 19, 2026 12:21 pm | — | Guggenheim | $45.00 | $35.76 | TheFly | NewAmsterdam Pharma price target raised to $45 from $41 at Guggenheim |
| January 21, 2026 11:35 am | — | RBC Capital | $47.00 | $32.41 | TheFly | NewAmsterdam Pharma price target raised to $47 from $44 at RBC Capital |
| January 6, 2026 9:33 am | Roanna Ruiz | Leerink Partners | $55.00 | $33.48 | StreetInsider | NewAmsterdam Pharma Co NV (NAMS) PT Raised to $55 at Leerink Partners |
| December 2, 2025 11:38 am | — | Goldman Sachs | $37.00 | $39.61 | TheFly | NewAmsterdam Pharma price target raised to $37 from $30 at Goldman Sachs |
| October 20, 2025 10:16 am | Joseph Pantginis | H.C. Wainwright | $52.00 | $36.40 | TheFly | NewAmsterdam Pharma assumed with a Buy at H.C. Wainwright |
| August 25, 2025 9:53 am | — | Wells Fargo | $45.00 | $24.70 | TheFly | NewAmsterdam Pharma initiated with an Overweight at Wells Fargo |
| March 3, 2025 1:48 pm | — | UBS | $41.00 | $20.27 | TheFly | NewAmsterdam Pharma price target raised to $41 from $35 at Guggenheim |
| December 30, 2024 11:11 am | Ed Arce | H.C. Wainwright | $48.00 | $25.60 | TheFly | NewAmsterdam Pharma initiated with a Buy at H.C. Wainwright |
| November 20, 2024 9:10 pm | Roanna Ruiz | Leerink Partners | $45.00 | $20.01 | StreetInsider | NewAmsterdam Pharma Co NV (NAMS) PT Raised to $45 at Leerink Partners |
Latest News for NAMS
NAARDEN, The Netherlands and MIAMI, July 02, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or…
NAARDEN, the Netherlands and MIAMI, July 01, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or…
NewAmsterdam Pharma Company N.V. (NAMS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
NAARDEN, The Netherlands and MIAMI, June 03, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or…
NAARDEN, the Netherlands and MIAMI, May 28, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for NAMS.
U.S. House Trading
No House trades found for NAMS.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.